Table 1.
Outcomes of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy groups in the cohort study.
| Variable | Before matchinga |
After matchingb |
High-risk score groupc |
Low-risk score groupd |
||||
|---|---|---|---|---|---|---|---|---|
| RR (95% CI) | P value | RR (95% CI) | P value | RR (95% CI) | P value | RR (95% CI) | P value | |
| All patients | ||||||||
| R0 resection: | 1·00 (0·95 to 1·05) | 1·000 | 0·99 (0·92 to 1·06) | 0·788 | 1·04 (0·95 to 1·13) | 0·396 | 0·98 (0·93 to 1·04) | 0·450 |
| ypN0 | 1·50 (1·15 to 1·95) | 0·003 | 1·31 (0·94 to 1·82) | 0·111 | 2·42 (1·17 to 5·03) | 0·017 | 1·17 (0·91 to 1·51) | 0·221 |
| ypN+ | 0·68 (0·55 to 0·84) | <0·001 | 0·76 (0·57 to 1·02) | 0·062 | 0·77 (0·61 to 0·96) | 0·028 | 0·73 (0·51 to 1·04) | 0·085 |
| Survival rate: | ||||||||
| 1-year | 1·08 (1·01 to 1·16) | 0·024 | 1·12 (1·02 to 1·23) | 0·018 | 1·26 (1·06 to 1·49) | 0·009 | 0·98 (0·94 to 1·02) | 0·342 |
| 3-year | 1·03 (0·89 to 1·19) | 0·692 | 1·07 (0·89 to 1·28) | 0·472 | 1·31 (0·94 to 1·80) | 0·111 | 0·87 (0·76 to 1·00) | 0·044 |
| 5-year | 1·77 (1·36 to 2·31) | <0·001 | 1·99 (1·43 to 2·78) | <0·001 | 3·94 (1·95 to 7·95) | <0·001 | 1·35 (1·02 to 1·78) | 0·036 |
| Patients with adenocarcinoma | ||||||||
| R0 resection: | 1·08 (0·93 to 1·25) | 0·313 | 1·66 (1·16 to 2·39) | 0·006 | 1·25 (0·88 to 1·78) | 0·213 | 1·00 (0·88 to 1·15) | 1·000 |
| ypN0 | 1·78 (0·96 to 3·32) | 0·067 | 1·22 (0·70 to 2·11) | 0·483 | 7·04 (0·47 to 106·34) | 0·158 | 1·40 (0·79 to 2·46) | 0·249 |
| ypN+ | 0·63 (0·46 to 0·88) | 0·004 | 2·61 (1·21 to 5·64) | 0·014 | 0·78 (0·52 to 1·16) | 0·230 | 0·66 (0·39 to 1·13) | 0·122 |
| Survival rate: | ||||||||
| 1-year | 1·21 (1·00 to 1·48) | 0·050 | 1·19 (1·04 to 1·36) | 0·011 | 3·80 (1·31 to 11·01) | 0·014 | 0·97 (0·94 to 0·99) | 0·057 |
| 3-year | 0·88 (0·72 to 1·09) | 0·212 | 0·96 (0·80 to 1·15) | 0·661 | 2·98 (0·87 to 10·23) | 0·082 | 0·73 (0·66 to 0·80) | <0·001 |
| 5-year | 1·99 (1·12 to 3·56) | 0·019 | 2·35 (1·58 to 3·50) | <0·001 | 2·60 (0·75 to 8·96) | 0·132 | 1·52 (0·86 to 2·67) | 0·150 |
| Patients with squamous cell carcinoma | ||||||||
| R0 resection: | 0·98 (0·93 to 1·04) | 0·450 | 0·97 (0·91 to 1·04) | 0·350 | 0·99 (0·89 to 1·09) | 0·853 | 0·98 (0·92 to 1·06) | 0·531 |
| ypN0 | 1·56 (1·13 to 2·14) | 0·007 | 0·74 (0·51 to 1·10) | 0·113 | 1·98 (0·85 to 4·61) | 0·113 | 1·25 (0·92 to 1·69) | 0·154 |
| ypN+ | 0·61 (0·43 to 0·88) | 0·006 | 1·25 (0·86 to 1·80) | 0·242 | 0·74 (0·51 to 1·09) | 0·113 | 0·60 (0·32 to 1·10) | 0·111 |
| Variable | RR (95% CI) | P value | RR (95% CI) | P value | RR (95% CI) | P value | RR (95% CI) | P value |
| Survival rate: | ||||||||
| 1-year | 1·04 (0·95 to 1·13) | 0·396 | 1·22 (1·00 to 1·49) | 0·050 | 1·04 (0·85 to 1·28) | 0·703 | 1·00 (0·95 to 1·06) | 1·000 |
| 3-year | 1·09 (0·89 to 1·33) | 0·405 | 0·99 (0·78 to 1·26) | 0·934 | 1·16 (0·75 to 1·78) | 0·505 | 0·97 (0·78 to 1·20) | 0·784 |
| 5-year | 1·84 (1·32 to 2·56) | <0·001 | 2·47 (1·37 to 4·46) | 0·003 | 3·85 (1·74 to 8·54) | <0·001 | 1·41 (0·98 to 2·01) | 0·064 |
The x2 exact test was used to obtain the P values. RR=risk ratio; CI=confidence interval; pCR=pathologic complete response; yp=postneoadjuvant pathologic; N0=no regional lymph node metastasis; N+=metastasis in regional lymph nodes; NR=not reached.
a
Study patients before machine learning-based propensity score matching.
b
Study patients after machine learning-based propensity score matching.
c
Study patients with a high-risk score in our prediction model.
d
Study patients with a low-risk score in our prediction model.